- Home
- DGICA vs ERAS Comparison
DGICA vs ERAS Comparison
Compare DGICA & ERAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DGICA
- ERAS
- Stock Information
- Founded
- DGICA 1986
- ERAS 2018
- Country
- DGICA United States
- ERAS United States
- Employees
- DGICA N/A
- ERAS N/A
- Industry
- DGICA Property-Casualty Insurers
- ERAS Biotechnology: Pharmaceutical Preparations
- Sector
- DGICA Finance
- ERAS Health Care
- Exchange
- DGICA Nasdaq
- ERAS Nasdaq
- Market Cap
- DGICA 510.1M
- ERAS 432.6M
- IPO Year
- DGICA N/A
- ERAS 2021
- Fundamental
- Price
- DGICA $17.86
- ERAS $1.54
- Analyst Decision
- DGICA
- ERAS Strong Buy
- Analyst Count
- DGICA 0
- ERAS 6
- Target Price
- DGICA N/A
- ERAS $5.42
- AVG Volume (30 Days)
- DGICA 111.8K
- ERAS 1.3M
- Earning Date
- DGICA 04-24-2025
- ERAS 05-07-2025
- Dividend Yield
- DGICA 3.86%
- ERAS N/A
- EPS Growth
- DGICA 1022.92
- ERAS N/A
- EPS
- DGICA 1.50
- ERAS N/A
- Revenue
- DGICA $989,605,000.00
- ERAS N/A
- Revenue This Year
- DGICA N/A
- ERAS N/A
- Revenue Next Year
- DGICA $4.06
- ERAS N/A
- P/E Ratio
- DGICA $11.88
- ERAS N/A
- Revenue Growth
- DGICA 6.71
- ERAS N/A
- 52 Week Low
- DGICA $12.26
- ERAS $1.23
- 52 Week High
- DGICA $18.19
- ERAS $3.45
- Technical
- Relative Strength Index (RSI)
- DGICA 71.44
- ERAS 48.32
- Support Level
- DGICA $15.26
- ERAS $1.23
- Resistance Level
- DGICA $18.09
- ERAS $1.56
- Average True Range (ATR)
- DGICA 0.64
- ERAS 0.13
- MACD
- DGICA 0.10
- ERAS 0.04
- Stochastic Oscillator
- DGICA 89.49
- ERAS 93.94
About DGICA Donegal Group Inc.
Donegal Group Inc is an insurance holding company that offers businesses and individuals personal and commercial lines of property and casualty insurance. The company's reportable segments are its Investment function, Personal lines of insurance, and Commercial lines of insurance. Personal lines products consist mainly of homeowners and private passenger automobile policies. The Commercial lines products of its insurance subsidiaries consist mainly of commercial automobile, commercial multi-peril, and workers' compensation policies. The group mainly operates in the United States.
About ERAS Erasca Inc.
Erasca Inc is a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's pipeline includes; Naporafenib, a pan-RAF inhibitor with first-in-class potential in NRASm melanoma, RAS Q61X tissue agnostic solid tumors, and other RAS/MAPK pathway-driven tumors, and ERAS-007 (oral ERK1/2 inhibitor) and ERAS-601 (oral SHP2 inhibitor), which target downstream and upstream nodes, respectively, of the RAS/MAPK pathway.